Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

Richard Kennedy; M. Bylesjo; Deborah Kerr; T. Davison; J.M. Black; E.W. Kay; R.J. Holt; V. Proutski; M. Ahdesmaki; V. Farztdinov; N. Goffard; P. Hey; F. McDyer; K. Mulligan; Julie Mussen; E. O'Brien; G. Oliver; S.M. Walker; Jude Mulligan; C. Wilson; A. Winter; D. O'Donoghue; H. Mulcahy; J. O'Sullivan; K. Sheahan; J. Hyland; R. Dhir; O.F. Bathe; O. Winqvist; U. Manne; C. Shanmugam; S. Ramaswamy; E.J. Leon; W.I. Smith; Ultan McDermott; Richard Wilson; Daniel Longley; J. Marshall; R. Cummins; D.J. Sargent; Patrick Johnston; Paul Harkin

doi:10.1200/JCO.2011.35.4498

Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

Richard Kennedy
, M. Bylesjo
, Deborah Kerr
, T. Davison
, J.M. Black
, E.W. Kay
, R.J. Holt
, V. Proutski
, M. Ahdesmaki
, V. Farztdinov
, N. Goffard
, P. Hey
, F. McDyer
, K. Mulligan
, Julie Mussen
, E. O'Brien
, G. Oliver
, S.M. Walker
, Jude Mulligan
, C. Wilson

A. Winter, D. O'Donoghue, H. Mulcahy, J. O'Sullivan, K. Sheahan, J. Hyland, R. Dhir, O.F. Bathe, O. Winqvist, U. Manne, C. Shanmugam, S. Ramaswamy, E.J. Leon, W.I. Smith, Ultan McDermott, Richard Wilson, Daniel Longley, J. Marshall, R. Cummins, D.J. Sargent, Patrick Johnston, Paul Harkin

Research output: Contribution to journal › Article › peer-review

185 Citations (Scopus)

Abstract

Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P <.001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P <.001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P <.001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples. © 2011 by American Society of Clinical Oncology.

Original language	English
Pages (from-to)	4620-4626
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	29
Issue number	35
DOIs	https://doi.org/10.1200/JCO.2011.35.4498
Publication status	Published - 10 Dec 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1200/JCO.2011.35.4498

Cite this

Kennedy, R., Bylesjo, M., Kerr, D., Davison, T., Black, J. M., Kay, E. W., Holt, R. J., Proutski, V., Ahdesmaki, M., Farztdinov, V., Goffard, N., Hey, P., McDyer, F., Mulligan, K., Mussen, J., O'Brien, E., Oliver, G., Walker, S. M., Mulligan, J., ... Harkin, P. (2011). Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue. Journal of Clinical Oncology, 29(35), 4620-4626. https://doi.org/10.1200/JCO.2011.35.4498

@article{e5ca2dc5cb6947dab0948816f7b8dc2d,

title = "Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue",

abstract = "Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P <.001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P <.001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P <.001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples. {\textcopyright} 2011 by American Society of Clinical Oncology.",

author = "Richard Kennedy and M. Bylesjo and Deborah Kerr and T. Davison and J.M. Black and E.W. Kay and R.J. Holt and V. Proutski and M. Ahdesmaki and V. Farztdinov and N. Goffard and P. Hey and F. McDyer and K. Mulligan and Julie Mussen and E. O'Brien and G. Oliver and S.M. Walker and Jude Mulligan and C. Wilson and A. Winter and D. O'Donoghue and H. Mulcahy and J. O'Sullivan and K. Sheahan and J. Hyland and R. Dhir and O.F. Bathe and O. Winqvist and U. Manne and C. Shanmugam and S. Ramaswamy and E.J. Leon and W.I. Smith and Ultan McDermott and Richard Wilson and Daniel Longley and J. Marshall and R. Cummins and D.J. Sargent and Patrick Johnston and Paul Harkin",

note = "MEDLINE{\textregistered} is the source for the MeSH terms of this document.",

year = "2011",

month = dec,

day = "10",

doi = "10.1200/JCO.2011.35.4498",

language = "English",

volume = "29",

pages = "4620--4626",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "35",

}

Kennedy, R, Bylesjo, M, Kerr, D, Davison, T, Black, JM, Kay, EW, Holt, RJ, Proutski, V, Ahdesmaki, M, Farztdinov, V, Goffard, N, Hey, P, McDyer, F, Mulligan, K, Mussen, J, O'Brien, E, Oliver, G, Walker, SM, Mulligan, J, Wilson, C, Winter, A, O'Donoghue, D, Mulcahy, H, O'Sullivan, J, Sheahan, K, Hyland, J, Dhir, R, Bathe, OF, Winqvist, O, Manne, U, Shanmugam, C, Ramaswamy, S, Leon, EJ, Smith, WI, McDermott, U, Wilson, R, Longley, D, Marshall, J, Cummins, R, Sargent, DJ, Johnston, P & Harkin, P 2011, 'Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue', Journal of Clinical Oncology, vol. 29, no. 35, pp. 4620-4626. https://doi.org/10.1200/JCO.2011.35.4498

TY - JOUR

T1 - Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

AU - Kennedy, Richard

AU - Bylesjo, M.

AU - Kerr, Deborah

AU - Davison, T.

AU - Black, J.M.

AU - Kay, E.W.

AU - Holt, R.J.

AU - Proutski, V.

AU - Ahdesmaki, M.

AU - Farztdinov, V.

AU - Goffard, N.

AU - Hey, P.

AU - McDyer, F.

AU - Mulligan, K.

AU - Mussen, Julie

AU - O'Brien, E.

AU - Oliver, G.

AU - Walker, S.M.

AU - Mulligan, Jude

AU - Wilson, C.

AU - Winter, A.

AU - O'Donoghue, D.

AU - Mulcahy, H.

AU - O'Sullivan, J.

AU - Sheahan, K.

AU - Hyland, J.

AU - Dhir, R.

AU - Bathe, O.F.

AU - Winqvist, O.

AU - Manne, U.

AU - Shanmugam, C.

AU - Ramaswamy, S.

AU - Leon, E.J.

AU - Smith, W.I.

AU - McDermott, Ultan

AU - Wilson, Richard

AU - Longley, Daniel

AU - Marshall, J.

AU - Cummins, R.

AU - Sargent, D.J.

AU - Johnston, Patrick

AU - Harkin, Paul

N1 - MEDLINE® is the source for the MeSH terms of this document.

PY - 2011/12/10

Y1 - 2011/12/10

N2 - Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P <.001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P <.001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P <.001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples. © 2011 by American Society of Clinical Oncology.

AB - Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P <.001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P <.001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P <.001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples. © 2011 by American Society of Clinical Oncology.

UR - https://www.scopus.com/pages/publications/83355174077

U2 - 10.1200/JCO.2011.35.4498

DO - 10.1200/JCO.2011.35.4498

M3 - Article

C2 - 22067406

SN - 0732-183X

VL - 29

SP - 4620

EP - 4626

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 35

ER -

Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

Cite this

Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Impacts

Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

Cite this